Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 2/20 | 0.53 |
| ▸ | MET | P08581 | 12/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.43 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772866 | 0.90 | MET (0.49) | PTK2BMETKDRPDGFRAIGF1R | |
| SCHEMBL1396814 | 0.88 | PTK2B (0.53) | PTK2BMETKDRPDGFRAIGF1R | |
| SCHEMBL1396796 | 0.87 | PTK2B (0.54) | PTK2BMETKDRPDGFRAKIT | |
| SCHEMBL1396752 | 0.87 | PTK2B (0.51) | PTK2BMETKDRPDGFRAIGF1R | |
| SCHEMBL1396760 | 0.85 | PTK2B (0.57) | PTK2BMETKDRPDGFRAIGF1R | |
| SCHEMBL1396843 | 0.82 | PTK2B (0.58) | PTK2BMETKDRPDGFRAIGF1R | |
| SCHEMBL1396736 | 0.79 | PTK2B (0.53) | PTK2BMETKDRPDGFRAKIT | |
| SCHEMBL4832074 | 0.78 | PTK2B (0.45) | PTK2BMETKDRPDGFRAIGF1R | |
| SCHEMBL1396757 | 0.78 | PTK2B (0.46) | PTK2BMETKDRPDGFRAKIT | |
| SCHEMBL1396735 | 0.77 | PTK2B (0.54) | PTK2BMETKDRPDGFRAKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288383-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2011-03-02 | — | — | EP | claimed |
| WO-2009140549-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2009-11-19 | — | — | WO | claimed |
| EP-1881976-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Amgen Inc., (US) | 2008-01-30 | — | — | EP | claimed |
| WO-2006116713-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | claimed |
| EP-2288383-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009140549-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-1881976-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Amgen Inc., (US) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006116713-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |